Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) is a healthcare company (biotechnology) based in the United States. The share price is $96.18, down 3.08% on the day, which values the company at $6.52B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.

Key facts

Share price
$96.18−3.08% today
Market value
$6.52B
200-week average
$34.15182% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Oruka Therapeutics, Inc. in more detail

ORKA trades at -33.6× next year's expected earnings. It sits 182% above its 200-week average of $34.15.

In its favour: More cash than debt. Worth checking: Share count keeps rising.

3 of the superinvestors tracked here hold ORKA, including Peter Kolchinsky (1.3% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio).

Superinvestors holding ORKA

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:ORKA vs CHE (Oruka Therapeutics, Inc. vs Chemed)ORKA vs AXSM (Oruka Therapeutics, Inc. vs Axsome Therapeutics)ORKA vs ARWR (Oruka Therapeutics, Inc. vs Arrowhead Pharmaceuticals)ORKA vs MSA (Oruka Therapeutics, Inc. vs MSA Safety)ORKA vs IMVT (Oruka Therapeutics, Inc. vs Immunovant)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Oruka Therapeutics, Inc. (ORKA): questions and answers

What is Oruka Therapeutics, Inc.'s market cap?

Oruka Therapeutics, Inc. is valued at $6.52B at a share price of $96.18.

Is ORKA above its 200-week moving average?

Yes. ORKA is 181.6% above its 200-week average of $34.15. Long-term investors watch that line because strong companies rarely trade below it for long.

Does ORKA pay a dividend?

Oruka Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own ORKA?

In their latest quarterly filings, Peter Kolchinsky (1.3% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio) hold ORKA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Oruka Therapeutics, Inc. (ORKA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ORKA

Underlying data: Yahoo Finance; company filings with the SEC.